# Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

> **NCT00414609** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 820 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00414609
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-09
- **Final completion:** 2011-07
- **Target enrollment:** 820 (ACTUAL)
- **Last updated:** 2012-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414609, "Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00414609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*